Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    July 2019
  1. SEKIYA A, Suzuki S, Tanaka A, Hattori S, et al
    Interleukin33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
    Int J Oncol. 2019 Jul 17. doi: 10.3892/ijo.2019.4845.
    PubMed     Text format     Abstract available


    June 2019
  2. JIANG S, Chang H, Deng S, Fan D, et al
    Icariin enhances the chemosensitivity of cisplatinresistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Int J Oncol. 2019;54:1933-1942.
    PubMed     Text format     Abstract available


    May 2019
  3. WANG L, Chen T, Li X, Yan W, et al
    USP39 promotes ovarian cancer malignant phenotypes and carboplatin chemoresistance.
    Int J Oncol. 2019 May 29. doi: 10.3892/ijo.2019.4818.
    PubMed     Text format     Abstract available


  4. GUAN W, Wang X, Lin Q, Zhang J, et al
    Transforming growth factorbeta/miR1433p/cystatin B axis is a therapeutic target in human ovarian cancer.
    Int J Oncol. 2019 May 28. doi: 10.3892/ijo.2019.4815.
    PubMed     Text format     Abstract available


  5. KIM BI, Kim JH, Sim DY, Nam M, et al
    Inhibition of JAK2/STAT3 and activation of caspase9/3 are involved in KYS05090Sinduced apoptosis in ovarian cancer cells.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4795.
    PubMed     Text format     Abstract available


  6. BU S, Li B, Wang Q, Gu T, et al
    Epithelial ovarian cancer stemlike cells are resistant to the cellular lysis of cytokineinduced killer cells via HIF1Amediated downregulation of ICAM1.
    Int J Oncol. 2019 May 3. doi: 10.3892/ijo.2019.4794.
    PubMed     Text format     Abstract available


  7. ZHA H, Li X, Sun H, Duan L, et al
    S100A9 promotes the proliferation and migration of cervical cancer cells by inducing epithelialmesenchymal transition and activating the Wnt/betacatenin pathway.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4793.
    PubMed     Text format     Abstract available


  8. ZHOU Y, Wang W, Wei R, Jiang G, et al
    Serum bradykinin levels as a diagnostic marker in cervical cancer with a potential mechanism to promote VEGF expression via BDKRB2.
    Int J Oncol. 2019 May 2. doi: 10.3892/ijo.2019.4792.
    PubMed     Text format     Abstract available


    March 2019
  9. HERNANDEZ-JUAREZ J, Vargas-Sierra O, Herrera LA, Cantu De Leon D, et al
    Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer.
    Int J Oncol. 2019 Mar 14. doi: 10.3892/ijo.2019.4749.
    PubMed     Text format     Abstract available


  10. ZHANG W, Ou X, Wu X
    Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis.
    Int J Oncol. 2019 Mar 7. doi: 10.3892/ijo.2019.4742.
    PubMed     Text format     Abstract available


    February 2019
  11. LEE J, An S, Jung JH, Kim K, et al
    MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4730.
    PubMed     Text format     Abstract available


  12. CHEN YN, Ren CC, Yang L, Nai MM, et al
    MicroRNA let7d5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.
    Int J Oncol. 2019 Feb 27. doi: 10.3892/ijo.2019.4731.
    PubMed     Text format     Abstract available


    January 2019
  13. LIU L, Yang L, Chang H, Chen YN, et al
    CP31398 attenuates endometrial cancer cell invasion, metastasis and resistance to apoptosis by downregulating MDM2 expression.
    Int J Oncol. 2019 Jan 9. doi: 10.3892/ijo.2019.4681.
    PubMed     Text format     Abstract available


    December 2018
  14. TAE IH, Park EY, Dey P, Son JY, et al
    Novel SIRT1 inhibitor 15-deoxy-Delta12,14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells.
    Int J Oncol. 2018;53:2518-2530.
    PubMed     Text format     Abstract available


    November 2018
  15. LI S, Zhao X, Chang S, Li Y, et al
    ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.
    Int J Oncol. 2018 Nov 7. doi: 10.3892/ijo.2018.4628.
    PubMed     Text format     Abstract available


  16. CHEN J, Jia Y, Jia ZH, Zhu Y, et al
    Silencing the expression of MTDH increases the radiation sensitivity of SKOV3 ovarian cancer cells and reduces their proliferation and metastasis.
    Int J Oncol. 2018;53:2180-2190.
    PubMed     Text format     Abstract available


  17. LIU S, Wang F, Liu G
    Knockdown of pleiotrophin increases the risk of preeclampsia following vitrified-thawed embryo transfer.
    Int J Oncol. 2018;53:1847-1856.
    PubMed     Text format     Abstract available


  18. LIU J, Zhen YZ, Cui J, Hu G, et al
    Dynamic influence of Rhein lysinate on HeLa cells.
    Int J Oncol. 2018;53:2047-2055.
    PubMed     Text format     Abstract available


    September 2018
  19. NING L, Long B, Zhang W, Yu M, et al
    Circular RNA profiling reveals circEXOC6B and circN4BP2L2 as novel prognostic biomarkers in epithelial ovarian cancer.
    Int J Oncol. 2018 Sep 20. doi: 10.3892/ijo.2018.4566.
    PubMed     Text format     Abstract available


    August 2018
  20. PAPPA KI, Christou P, Xholi A, Mermelekas G, et al
    Membrane proteomics of cervical cancer cell lines reveal insights on the process of cervical carcinogenesis.
    Int J Oncol. 2018 Aug 7. doi: 10.3892/ijo.2018.4518.
    PubMed     Text format     Abstract available


    July 2018
  21. SKIRNISDOTTIR I, Akerud H, Seidal T
    Clinical significance of growth factor receptor EGFR and angiogenesis regulator VEGFR2 in patients with ovarian cancer at FIGO stages I-II.
    Int J Oncol. 2018 Jul 31. doi: 10.3892/ijo.2018.4511.
    PubMed     Text format     Abstract available


  22. YOSHIDA M, Taguchi A, Kawana K, Ogishima J, et al
    Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
    Int J Oncol. 2018 Jul 26. doi: 10.3892/ijo.2018.4504.
    PubMed     Text format     Abstract available


  23. LV Q, Wu K, Liu F, Wu W, et al
    Interleukin17A and heparanase promote angiogenesis and cell proliferation and invasion in cervical cancer.
    Int J Oncol. 2018 Jul 26. doi: 10.3892/ijo.2018.4503.
    PubMed     Text format     Abstract available


  24. LIU J, Zheng M, Qi Y, Wang H, et al
    Lewis(y) antigen-mediated positive feedback loop induces and promotes chemotherapeutic resistance in ovarian cancer.
    Int J Oncol. 2018 Jul 20. doi: 10.3892/ijo.2018.4496.
    PubMed     Text format     Abstract available


  25. XU Y, Gao W, Zhang Y, Wu S, et al
    ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
    Int J Oncol. 2018 Jul 9. doi: 10.3892/ijo.2018.4476.
    PubMed     Text format     Abstract available


    June 2018
  26. LIU J, Liu D, Liu JJ, Zhao C, et al
    Blocking the Nav1.5 channel using eicosapentaenoic acid reduces migration and proliferation of ovarian cancer cells.
    Int J Oncol. 2018 Jun 12. doi: 10.3892/ijo.2018.4437.
    PubMed     Text format     Abstract available


  27. MUNGUIA-MORENO JA, Diaz-Chavez J, Garcia-Villa E, Albino-Sanchez ME, et al
    Early synergistic interactions between the HPV16E7 oncoprotein and 17beta-oestradiol for repressing the expression of Granzyme B in a cervical cancer model.
    Int J Oncol. 2018 Jun 6. doi: 10.3892/ijo.2018.4432.
    PubMed     Text format     Abstract available


    May 2018
  28. KANG MA, Kim W, Jo HR, Shin YJ, et al
    Anticancer and radiosensitizing effects of the cyclin-dependent kinase inhibitors, AT7519 and SNS032, on cervical cancer.
    Int J Oncol. 2018 May 31. doi: 10.3892/ijo.2018.4424.
    PubMed     Text format     Abstract available


  29. SONG J, Zhang W, Wang S, Liu K, et al
    A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    Int J Oncol. 2018 May 11. doi: 10.3892/ijo.2018.4403.
    PubMed     Text format     Abstract available


  30. SHEN L, Sun B, Sheng J, Yu S, et al
    PGC1alpha promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
    Int J Oncol. 2018 May 9. doi: 10.3892/ijo.2018.4401.
    PubMed     Text format     Abstract available


    April 2018
  31. QIU C, Wang Y, Wang X, Zhang Q, et al
    Combination of TP53 and AGR3 to distinguish ovarian high-grade serous carcinoma from low-grade serous carcinoma.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4360.
    PubMed     Text format     Abstract available


  32. WANG Y, Qiu C, Lu N, Liu Z, et al
    FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Int J Oncol. 2018 Apr 4. doi: 10.3892/ijo.2018.4359.
    PubMed     Text format     Abstract available


    March 2018
  33. TANG G, Guo J, Zhu Y, Huang Z, et al
    Metformin inhibits ovarian cancer via decreasing H3K27 trimethylation.
    Int J Oncol. 2018 Mar 29. doi: 10.3892/ijo.2018.4343.
    PubMed     Text format     Abstract available


  34. KIM SY, Kwon SK, Lee SY, Baek KH, et al
    Ubiquitin-specific peptidase 5 and ovarian tumor deubiquitinase 6A are differentially expressed in p53+/+ and p53-/- HCT116 cells.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4302.
    PubMed     Text format     Abstract available


    February 2018
  35. TIAN R, Li X, Gao Y, Li Y, et al
    Identification and validation of the role of matrix metalloproteinase-1 in cervical cancer.
    Int J Oncol. 2018 Feb 7. doi: 10.3892/ijo.2018.4267.
    PubMed     Text format     Abstract available


  36. YUAN Y, Ye HQ, Ren QC
    Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer.
    Int J Oncol. 2018;52:461-472.
    PubMed     Text format     Abstract available


    January 2018
  37. XU M, Xiao J, Chen M, Yuan L, et al
    miR1495p promotes chemotherapeutic resistance in ovarian cancer via the inactivation of the Hippo signaling pathway.
    Int J Oncol. 2018 Jan 24. doi: 10.3892/ijo.2018.4252.
    PubMed     Text format     Abstract available


  38. SATO N, Saga Y, Uchibori R, Tsukahara T, et al
    Eradication of cervical cancer in vivo by an AAV vector that encodes shRNA targeting human papillomavirus type 16 E6/E7.
    Int J Oncol. 2018 Jan 15. doi: 10.3892/ijo.2018.4245.
    PubMed     Text format     Abstract available


  39. WANG Y, Yu X, Song H, Feng D, et al
    The STAT-ROS cycle extends IFNinduced cancer cell apoptosis.
    Int J Oncol. 2018;52:305-313.
    PubMed     Text format     Abstract available


    November 2017
  40. CHANG RK, Li X, Mu N, Hrydziuszko O, et al
    MicroRNA expression profiles in nonepithelial ovarian tumors.
    Int J Oncol. 2017 Nov 10. doi: 10.3892/ijo.2017.4200.
    PubMed     Text format     Abstract available


    October 2017
  41. PENG F, Zhong Y, Liu Y, Zhang Y, et al
    SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.
    Int J Oncol. 2017 Oct 19. doi: 10.3892/ijo.2017.4168.
    PubMed     Text format     Abstract available


  42. OZRETIC P, Trnski D, Musani V, Maurac I, et al
    Non-canonical Hedgehog signaling activation in ovarian borderline tumors and ovarian carcinomas.
    Int J Oncol. 2017 Oct 12. doi: 10.3892/ijo.2017.4156.
    PubMed     Text format     Abstract available


  43. SHETA R, Bachvarova M, Plante M, Gregoire J, et al
    Altered expression of different GalNActransferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer.
    Int J Oncol. 2017 Oct 9. doi: 10.3892/ijo.2017.4147.
    PubMed     Text format     Abstract available


  44. PAN H, Wang F, Rankin GO, Rojanasakul Y, et al
    Inhibitory effect of black tea pigments, theaflavin3/3'-gallate against cisplatin-resistant ovarian cancer cells by inducing apoptosis and G1 cell cycle arrest.
    Int J Oncol. 2017 Oct 3. doi: 10.3892/ijo.2017.4145.
    PubMed     Text format     Abstract available


  45. GUO J, Cai J, Zhang Y, Zhu Y, et al
    Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: A comparative study.
    Int J Oncol. 2017;51:1199-1208.
    PubMed     Text format     Abstract available


  46. LAI Y, Fan L, Zhao Y, Ge H, et al
    Cx32 suppresses extrinsic apoptosis in human cervical cancer cells via the NFkappaB signalling pathway.
    Int J Oncol. 2017;51:1159-1168.
    PubMed     Text format     Abstract available


    September 2017
  47. LIAO S, Xiao S, Chen H, Zhang M, et al
    The receptor for activated protein kinase C promotes cell growth, invasion and migration in cervical cancer.
    Int J Oncol. 2017 Sep 27. doi: 10.3892/ijo.2017.4137.
    PubMed     Text format     Abstract available


  48. BU S, Zhang Q, Wang Q, Lai D, et al
    Human amniotic epithelial cells inhibit growth of epithelial ovarian cancer cells via TGFbeta1-mediated cell cycle arrest.
    Int J Oncol. 2017 Sep 14. doi: 10.3892/ijo.2017.4123.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: